NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder ...

H.C. Wainwright lowered the firm’s price target on Nuvation Bio (NUVB) to $10 from $11 and keeps a Buy rating on the shares following the Q4 report. See what stocks are receiving Strong Buy ...

JonesResearch analyst Danya Ben-Hail initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $10 price target The company is focused on developing clinical stage targeted therapeutics with ...

Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s ...

Nuvation Bio has a 1 year low of $1.67 and a 1 year high of $4.16. The firm’s 50 day moving average price is $2.35 and its 200 day moving average price is $2.55.

Shares of Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) gapped down prior to trading on Monday after HC Wainwright lowered their price target on the stock from $11.00 to $10.00. The stock had ...

Nuvation Bio has secured $250m in non-dilutive financing from Sagard Healthcare Partners to fully fund the commercialisation of taletrectinib in the US. The financial move will support Nuvation ...

Fintel reports that on March 12, 2025, Jones Trading initiated coverage of Nuvation Bio (NYSE:NUVB) with a Buy recommendation. As of March 4, 2025, the average one-year price target for Nuvation ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief ...

"Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for ...